Novartis in the US – The Big Picture


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Novartis in the US – The Big Picture

  1. 1. Novartis in the US – The Big Picture Novartis is a world leader in the research and development of products that protect and improve health and well-being. Our global mission is to discover, develop and successfully market inno- vative products to ease suffering and enhance the quality of life. Novartis is the only major pharmaceutical company with leadership positions in both patented prescription medicines and generic pharmaceuticals. Over the years, Novartis has been recognized for its admirable reputation, commitment to ethics, its status as a respected pillar of the industry and for being an outstanding workplace for its employees. In recent years we’ve been named among the “Most Admired” (FORTUNE), “Most Respected” (Barron’s) and “Most Ethical” (Ethisphere) companies in the world. Our US organization is made up of companies divided into four divisions with active operations spanning 20 cities and responsible for generating nearly a third of our global revenue. Together, these units function side-by-side under the umbrella of Novartis Corporation, a US holding com- pany responsible for Group level matters such as finance, investor relations and communications. Novartis Group Total 2008 Global Sales: $41,459 million Novartis Group 2008 Global Sales by region: Novartis Group Total 2008 US Sales: $12,861 million Novartis Group 2008 US Sales by division: *The Novartis Consumer Health Division is made up of the OTC, Animal Health and CIBA VISION Business Units Total Novartis Group US employees: Approximately 22,000 Our US employees by division: *Includes NIBR and GNF associates US: 31% ($12,861M) Canada/LATAM: 8% ($3,425M) Asia/Africa/ Australia: 17% ($7,139M) Europe: 44% ($18,034M) Sandoz: 14% ($1,766M) NV&D: 6% ($765M) Pharmaceuticals: 67% ($8,616M) NCH*: 13% ($1,714M) Pharmaceuticals: 55% Research*: 14% Corporation: 0.5% Sandoz: 5.5% NV&D: 4.5% NCH: 20.5% WHAT WE DO • We are ranked as a leader for having one of the best combinations of growing brands and a promising pipeline. • Our clinical pipeline holds a broad stream of 152 projects including both new molecular entities and additional indications or formulations for marketed products. HOW WE WORK Our US divisions/business units include: • Novartis Pharmaceuticals • Novartis Oncology • Novartis Vaccines and Diagnostics (NV&D) • Sandoz (generics) • Novartis Institutes for BioMedical Research (NIBR) • OTC (over-the-counter medicines) • Novartis Animal Health • CIBA VISION WHO WE ARE • Novartis was created in 1996 by the merger of Swiss companies Ciba-Geigy and Sandoz. With global head- quarters in Basel, Switzerland, the Novartis Group companies employ nearly 98,000 people in more than 140 countries. • Our largest division was recently named to DiversityInc’s Top 50 Companies for diversity and Working Mother’s 100 Best Companies for 10 years running. For the Novartis Group, the US is a major center of research and development (R&D), manufacturing, sales and marketing. More than 20% of the Novartis Group’s employees are based here.
  2. 2. Novartis invests in these four strategic growth platforms Helping patients get access to needed medicines At Novartis, not only are we committed to making medicines, we are also dedicated to improv- ing access to them. We recognize that many patients today face obstacles that keep them from getting the medicines they need, so we work to lend a helping hand. • Last year, our patient assistance programs reached 74 million patients worldwide, with contri- butions totaling $1.26 billion. • In 2009, Novartis delivered its 250 millionth malaria treatment. With an estimated 630,000 lives saved, Novartis nonprofit Malaria Initiative is the largest access-to-medicines program for the developing world. • Since 2002, Novartis has donated more than one billion dollars’ worth of one of our breakthrough cancer treatments to patients and governments. • In the US, we are proud to offer Patient Assistance Now, an easy to use, comprehensive resource allowing patients to access programs that may help pay for their Novartis medicines and provide information they may need to take care of their health. The PHARMACEUTICALS DIVISION of Novartis is recognized worldwide for the innovative medicines we provide to patients, physicians and healthcare organizations. Our current product portfolio in therapeutic areas such as Cardiology, Oncology, Respiratory, and Neuroscience contains more than 50 key marketed prescription drugs, many of which are leaders in their respective fields. In our Oncology Business Unit, our employees share a common mission to discover and develop innovative medicines to fight cancer. Headquartered in Florham Park, New Jersey, we are passionate about providing a broad range of new remedies and practical solutions that change the way patients live with cancer. At NOVARTIS VACCINES AND DIAGNOSTICS, caring begins with prevention. Every 25 sec- onds, someone in the world is given a Novartis vaccine. Our division’s purpose is to look after the well-being of people through our innovative vaccines and diagnostics tools designed to prevent the spread of life-threatening diseases and protect vulnerable populations. Novartis Vaccines is focused on creating innovative products to prevent influenza, meningitis and more than 20 vaccine-preventable viral and bacterial diseases. Novartis Diagnostics is dedicated to preventing the spread of infectious diseases through sophisticated blood-testing equipment that screens blood donations for infection. In Cambridge, MA, NV&D researchers at the Center of Excellence in Virology are working on a vaccine for H1N1 influenza. SANDOZ is the generic pharmaceuticals division of Novartis and a global leader in the rapidly growing generics industry. Sandoz develops, produces and markets medicines no longer pro- tected by patents, along with pharmaceutical and biotechnological active substances, and sells them to wholesalers, pharmacies, hospitals and other healthcare outlets. Having cultivated the ability to develop and produce a wide range of difficult-to-make medicines, from complex delivery systems for standard generics to modern biopharmaceutical medicines (biosimilars), Sandoz stands out for making far more than just traditional off-patent medicines. Through our global network, Sandoz generic medicines are available to 90% of people worldwide. Our CONSUMER HEALTH DIVISION creates, develops and manufactures a wide range of products designed to restore, maintain or improve the health and well-being of consumers. A number of our products have become household brands in America, including Keri® , Excedrin® , TheraFlu® , Benefiber® , Triaminic® , Air Optix® , Dailies® and Sentinel® Flavor Tabs® . • OTC (i.e., “over-the-counter” products) is a world leader in the research, development, pro- duction and marketing of self-medication products that do not require a prescription. We have the fastest growing OTC company among the top five global players in the industry. • Novartis Animal Health focuses on the well-being of companion animals and the health and productivity of farm animals. Novartis produces the market-leading drug for heart disease in dogs and kidney failure in cats. • CIBA VISION is a global leader in the research, development and manufacturing of contact lenses and lens care products. CIBA VISION offers the widest variety of colors, modalities and color contact lens styles of any contact lens manufacturer.
  3. 3. The path from scientific breakthrough to suc- cessful pharmaceutical brand depends on mobilizing the best global resources, expertise and experience. At Novartis, we often achieve success through close collaboration with companies and institutions who share a common vision and complementary strengths. A key Novartis priority is to build winning collaborations in the research of new medicines and vaccines. For instance, through the NIBR Strategic Alliances Group, NIBR has established produc- tive alliances with over 300 collaborators, both academic and industrial. Current US collabo- rations include: • Alnylam Pharmaceuticals • CombinatoRx, Inc. • Dana Farber Cancer Institute • Gen-Probe, Inc. • Human Genome Sciences, Inc. • Idenix Pharmaceuticals, Inc. • Idera Pharmaceuticals, Inc. • Massachusetts General Hospital (MGH) • Massachusetts Institute of Technology (MIT) • The Institute for OneWorld Health • The Scripps Research Institute Research & Development in the US begins and ends with the patient Our strategy is to focus on discovery projects at the intersection of powerful scientific mechanisms and greatest medical need R&D collaborations across the US Novartis Institutes of BioMedical Research (NIBR) Three of six NIBR sites in the world are located in the US, focus- ing on diverse disease areas Cambridge, MA (Global HQ) • Oncology • Infectious diseases • Ophthalmology • Cardiovascular and metabolic- related diseases • Musculoskeletal diseases East Hanover, NJ • Cardiovascular and metabolic- related diseases Emeryville, CA • Oncology Genomics Institute of the Novartis Research Foundation (GNF) La Jolla, CA One of our four dedicated research institutes around the globe is in California. Researchers at GNF develop and apply advanced technologies to identify new biological processes and understand the underlying mechanisms of disease. Biologics are at the cutting-edge of drug discovery—they already represent a quarter of our R&D pipeline! The Novartis Biologics unit, launched in 2007, is dedicated to the ultimate goal of delivering customized, targeted biologic therapies that can improve the lives of patients. Scientists at Novartis are accelerating develop- ment of innovative medicines with cutting-edge tools and close cooperation among multi-dis- ciplinary teams to translate fundamental science into treatments. To do this, they are using the latest technologies and approaches to drug discovery—integrating clinical insights with mechanistic understanding of diseases to get an early readout on a drug’s safety and effectiveness. This enables us to find and advance the most promising drug candidates. Novartis completes proof-of-concept studies to confirm a medicine’s mechanism of action and explores multiple disease indications before full development begins. By also modeling the activity of medicines and vaccines, we are able to make better decisions and bring more and better new medicines to market in a shorter time. Collaborations with biotech and academia help further strengthen the clinical pipeline. NIBR associates in Cambridge, MA, are playing a role in developing the next generation of research talent through the Netpals program, which pairs Novartis scientists with local public school students for one-on-one mentoring and correspondence.
  4. 4. PATIENTS Novartis puts patients first. In 2008, the Novartis Patient Assistance Foundation provid- ed over $180 million worth of free product to 85,000 US patients. We are also a found- ing member of Together Rx Access, a prescription savings card that helps uninsured Americans better afford their prescription medicines. BUSINESS CONDUCT Novartis is committed to trans- parency in its business ethics and provides our associates with company-wide training and awareness programs on Ethics and Law Compliance, our Code of Conduct, and Corporate Citizenship. High standards of integrity are cen- tral to achieving responsible business activities. PEOPLE AND COMMUNITIES Novartis employees feel pas- sionate about where they live and work, so we support their volunteer efforts in local com- munities through funding and by working with them to ensure that they have the time, the resources and the energy to give back in a meaningful way. ENVIRONMENT Novartis aims to use natural resources efficiently and mini- mize the environmental impact of its activities and products during their lifecycles. We are working toward becoming a best-in-class leader in Health, Safety, and Environment (HSE), including energy efficiency and the reduction of CO2 emis- sions according to the Kyoto Protocol. Our commitment to Corporate Citizenship rests on four pillars Novartis in the US US headquarters for each Novartis division are detailed below. Of these, four are also the global headquarters for that business—NIBR, NV&D, OTC and CIBA VISION. Novartis Corporation East Hanover, NJ Novartis Institutes for BioMedical Research (NIBR) Cambridge, MA Novartis Pharmaceuticals Corporation East Hanover, NJ Novartis Vaccines and Diagnostics, Inc. Cambridge, MA Sandoz Inc. Princeton, NJ Novartis Consumer Health, Inc. (OTC) Parsippany, NJ Novartis Animal Health US, Inc. Greensboro, NC CIBA VISION Corporation Duluth, GA Genomics Institute of the Novartis Research Foundation (GNF) La Jolla, CA Learn more about the Novartis Group in the US at ©2009 Novartis Corporation Printed in USA NOV-900509 Printed on Recycled Paper Learn more about how Novartis endeavors to create value in society at New York, NY Florham Park, NJ Washington, DC Wilson, NC Holly Springs, NC Broomfield, CO Vacaville, CA San Carlos, CA La Jolla, CA Cidra, Puerto Rico Duluth, GA Greensboro, NC Princeton, NJ Parsippany, NJ Suffern, NY Des Plaines, IL Humacao, Puerto Rico Larchwood, IA Lincoln, NE Emeryville, CA East Hanover, NJ Cambridge, MA